Materia Medica Holding

Moscow, Russia

Materia Medica Holding

Moscow, Russia
SEARCH FILTERS
Time filter
Source Type

Lisachev P.D.,Russian Academy of Sciences | Pustylnyak V.O.,Russian Academy of Medical Sciences | Shtark M.B.,Russian Academy of Medical Sciences | Epstein O.I.,Materia Medica Holding
Bulletin of Experimental Biology and Medicine | Year: 2013

The effects of NMDA receptor blocker MK-801 on the increase in S100B protein mRNA content induced by long-term posttetanic potentiation in the hippocampal sections were studied. The level of S100B mRNA after 30-min tetanization in the presence of 10 μM MK-801 constituted 132% of the basal level, which was significantly (226%) lower than the control level. Hence, gene expression, induced by long-term posttetanic potentiation, in the glial cells (similarly as in the neurons) depended significantly on NMDA receptors. © 2013 Springer Science+Business Media New York.


Epstein O.I.,Materia Medica Holding
Bulletin of Experimental Biology and Medicine | Year: 2012

Multiple dilutions of the original substance release its peculiar activity referred to as "releaseactivity". Although this activity originates from the initial substance, it does not depend on its negligible concentration in extreme dilutions. Thus, the terms "dose", "ultralow dose", and "homeopathic dose", do not correctly describe the release-active solutions, since the concept of dose implies the presence of some part of the original substance in a dilution with its intrinsic therapeutic potency. The data are reported on the molecular and cellular mechanisms of the mode of action of the release-active agents, some of which being introduced into clinical practice. © 2012 Springer Science+Business Media New York.


Barchukov V.V.,Materia Medica Holding | Zhavbert E.S.,Materia Medica Holding | Dugina Y.L.,Materia Medica Holding | Epstein O.I.,Materia Medica Holding
Bulletin of Experimental Biology and Medicine | Year: 2015

The effectiveness of antibody-based release-active preparations Impaza (antibodies to eNOS), Tenoten (antibodies to brain-specific protein S-100), Dietressa (antibodies to type 1 cannabinoid receptor), Brizantin (combined preparation, antibodies to brain-specific protein S-100 and type 1 cannabinoid receptor), and Divaza (combined preparation, antibodies to brain-specific protein S-100 and eNOS) in the prevention of vertigo was studied on the model of intermittent accumulation of Coriolis accelerations (ICCA). Modification of activity of vestibular receptors and signal systems by release-active preparations contributed to an increase in ICCA tolerance time. Combined preparation Impaza possessed the most significant antinaupathic properties. Brizantin was less potent in this respect. © 2015, Springer Science+Business Media New York.


Gorbunov E.A.,Zen-Bio, Inc. | Nicoll J.,Zen-Bio, Inc. | Myslivets A.A.,Materia Medica Holding | Kachaeva E.V.,Materia Medica Holding | Tarasov S.A.,Materia Medica Holding
Bulletin of Experimental Biology and Medicine | Year: 2015

Addition of Subetta to insulin (10 nM) increased insulin-stimulated glucose uptake 43% (p<0.001). Moreover, glucose uptake stimulated by insulin (10 nM) in the presence of Subetta was similar to that stimulated by 300 nM insulin. These findings suggest that Subetta significantly enhanced insulin sensitivity of tissues through stimulation of glucose transport to myocytes mediated by glucose transporter 4. © 2015, Springer Science+Business Media New York.


PubMed | Materia Medica Holding
Type: Comparative Study | Journal: Bulletin of experimental biology and medicine | Year: 2015

The effectiveness of antibody-based release-active preparations Impaza (antibodies to eNOS), Tenoten (antibodies to brain-specific protein S-100), Dietressa (antibodies to type 1 cannabinoid receptor), Brizantin (combined preparation, antibodies to brain-specific protein S-100 and type 1 cannabinoid receptor), and Divaza (combined preparation, antibodies to brain-specific protein S-100 and eNOS) in the prevention of vertigo was studied on the model of intermittent accumulation of Coriolis accelerations (ICCA). Modification of activity of vestibular receptors and signal systems by release-active preparations contributed to an increase in ICCA tolerance time. Combined preparation Impaza possessed the most significant antinaupathic properties. Brizantin was less potent in this respect.


PubMed | E D Goldberg Research Institute Of Pharmacology And Regenerative Medicine and Materia Medica Holding
Type: Journal Article | Journal: Bulletin of experimental biology and medicine | Year: 2015

The anxiolytic and antidepressant activities of complex preparations divaza and brizantin containing antibodies to brain-specific protein S100 were estimated using Vogel conflict test and Nomura forced swimming test. Course treatment (5 days) of brizantin in a dose of 2.5 ml/kg and divaza in a dose of 7.5 ml/kg significantly increased punished drinking in the Vogel conflict test in comparison with the control. Both drugs also improved general emotional behavior during training prior to the test procedure. Brizantin and divaza in a dose of 7.5 ml/kg increased the number of wheel revolutions in the Nomura forced swimming test in comparison with the control; the effect of divaza was more pronounced. High correlation coefficients between the number of wheel revolutions during the first and second 5-min sessions are also indicative of antidepressant action of divaza and brizantin.


PubMed | Materia Medica Holding
Type: Comparative Study | Journal: Bulletin of experimental biology and medicine | Year: 2012

We compared two modifications of Vogel conflict test and assessed anxyolitic activity of two drugs: diazepam (benzodiazepine anxiolitic) and tenoten (ultra-low doses of antibodies to S-100 protein) in both modifications of the test. It was found that the intensity of anxiolitic effect of the drugs depends on the conditions of Vogel test.


PubMed | Materia Medica Holding
Type: Journal Article | Journal: Bulletin of experimental biology and medicine | Year: 2014

We studied the efficiency of Dietressa on body weight reduction in C57Bl/6 male mice feeding standard high-fat ration (24%). After 5-month daily intragastric administration of Dietressa, body weight gain was the lowest in comparison with other groups and did not differ from that in mice receiving the reference substance sibutramine for 5 months. In contrast to sibutramine, Dietressa did not increase motor activity of animals in the open field test and produced no anorectic effect. The mean body weight gain per each 1000 kcal of consumed food in the group of animals receiving Dietressa was lower than in the control group and mice receiving sibutramine.


PubMed | Zen-Bio, Inc. and Materia Medica Holding
Type: Journal Article | Journal: Bulletin of experimental biology and medicine | Year: 2015

Addition of Subetta to insulin (10 nM) increased insulin-stimulated glucose uptake 43% (p<0.001). Moreover, glucose uptake stimulated by insulin (10 nM) in the presence of Subetta was similar to that stimulated by 300 nM insulin. These findings suggest that Subetta significantly enhanced insulin sensitivity of tissues through stimulation of glucose transport to myocytes mediated by glucose transporter 4.


PubMed | Materia Medica Holding
Type: Journal Article | Journal: Bulletin of experimental biology and medicine | Year: 2012

Antidiabetic activity of Subetta was revealed on the model of streptozotocin-induced diabetes mellitus in rats. Intragastric administration of this preparation in a dose of 5 ml/kg for 50 days reduced blood glucose levels, urine levels of glucose and ketone bodies, restored glucose tolerance in the oral glucose test, improved general condition and increased the survival rate of animals. The effectiveness of the drug was not inferior to that of rosiglitazone (8 mg/kg).

Loading Materia Medica Holding collaborators
Loading Materia Medica Holding collaborators